# A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)

> **NCT06943833** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Locally Advanced Cervical Cancer

## Interventions

- **BIOLOGICAL:** Volrustomig

## Key facts

- **NCT ID:** NCT06943833
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-03-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06943833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06943833, "A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT06943833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*